- Conditions
- Myelodysplastic Syndrome (MDS), Chronic Lymphocytic Leukemia (CLL), Chemotherapy-sensitive Lymphoma, Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma, Acute Myelogenous Leukemia (AML), Acute Biphenotypic Leukemia (ABL), Acute Undifferentiated Leukemia (AUL)
- Interventions
- Fludarabine, Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5, Total Body Irradiation (TBI) 200cGy on Day -1, Infusion of non-T-cell depleted bone marrow on Day 0, Busulfan, Cyclophosphamide 50mg/kg/day IV on Days -2,-1, Cyclophosphamide 50mg/kg/day IV on Days -5,-4, Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1, Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4, Sirolimus, Mycophenolate mofetil, G-CSF, Pre-HCT Mesna on Days -6 and -5, Pre-HCT Mesna on Days -2 and -1, Pre-HCT Mesna on Days -5 and -4, Post-HCT Mesna
- Drug · Radiation · Procedure
- Lead sponsor
- Center for International Blood and Marrow Transplant Research
- Network
- Eligibility
- 15 Years to 70 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 11
- States / cities
- Gainesville, Florida • Miami, Florida • Tampa, Florida + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Neuroblastoma
- Interventions
- Vorinostat, 131- I Metaiodobenzylguanidine, Peripheral Blood Stem Cell Infusion, Filgrastim
- Drug · Radiation · Procedure
- Lead sponsor
- New Approaches to Neuroblastoma Therapy Consortium
- Other
- Eligibility
- 2 Years to 30 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more
- Conditions
- Small Bowel Bacterial Overgrowth, Gastrointestinal Diseases, Stomach Diseases, Digestive System Diseases
- Interventions
- Xifaxan, SmartPill, Lactulose hydrogen breath test (H_2BT)
- Drug · Device · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Autism Spectrum Disorder
- Interventions
- IGF-1, Placebo/saline
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 5 Years to 12 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- HER2-positive Breast Cancer
- Interventions
- [18F]-FDG
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 75 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Child Development
- Interventions
- Infant formula
- Other
- Lead sponsor
- Nature's One
- Industry
- Eligibility
- 1 Day to 14 Days
- Enrollment
- 216 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 24
- States / cities
- Tucson, Arizona • Newport, Arkansas • Searcy, Arkansas + 21 more
- Conditions
- Very Preterm and Extremely Preterm Birth
- Interventions
- Urine sodium testing, Serum sodium testing, Milk fortification
- Diagnostic Test · Dietary Supplement
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 0 Days to 14 Days
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 3
- States / cities
- Cincinnati, Ohio • Portland, Oregon • Seattle, Washington
- Conditions
- Gestational Weight Gain, Overweight and Obesity, Pregnancy, Energy Balance
- Interventions
- HMZ 2.0 Intervention, Attention Control Intervention
- Behavioral
- Lead sponsor
- Penn State University
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 144 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- University Park, Pennsylvania
- Conditions
- Obesity
- Interventions
- growth monitoring, Growth Monitoring plus Family-based Behavioral Counseling
- Behavioral
- Lead sponsor
- The University of Tennessee, Knoxville
- Other
- Eligibility
- 4 Years to 8 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 2
- States / cities
- Knoxville, Tennessee
- Conditions
- Anemia in Incident Dialysis Patients
- Interventions
- Roxadustat, Epoetin Alfa
- Drug
- Lead sponsor
- Kyntra Bio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,043 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 30
- States / cities
- Chula Vista, California • La Mesa, California • San Diego, California + 25 more
- Conditions
- ADHD, Growth
- Interventions
- behavior therapy, Extended release (ER) methylphenidate product, monitoring, drug holiday, caloric supplement
- Behavioral · Drug · Other + 1 more
- Lead sponsor
- Florida International University
- Other
- Eligibility
- 5 Years to 12 Years
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Lymphoma
- Interventions
- Health Education Program, SMART3RP-Lymphoma
- Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 254 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Metastatic Renal Cell Carcinoma, Metastatic Renal Cancer, Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma, Kidney Cancer, Translocation Renal Cell Carcinoma
- Interventions
- Sasanlimab, Palbociclib, Axitinib
- Drug
- Lead sponsor
- Stephanie Berg
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Cardiovascular Health
- Interventions
- ENRICH, Usual Home Visiting
- Behavioral
- Lead sponsor
- JHSPH Center for Clinical Trials
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 6,618 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2029
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • San Luis Obispo, California • Aurora, Colorado + 6 more
- Conditions
- Renal Cell Carcinoma
- Interventions
- Survey Questionnaire
- Other
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Infertility, Infertility, Female, Oocyte Retrieval, Postoperative Pain, Embryo Transfer
- Interventions
- Ketorolac (Toradol), Placebo (saline)
- Drug · Other
- Lead sponsor
- Shady Grove Fertility Reproductive Science Center
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 2
- States / cities
- Rockville, Maryland • Fairfax, Virginia
- Conditions
- Obesity
- Interventions
- Sugar reduction health education program, Control health education program, Home water delivery
- Behavioral · Other
- Lead sponsor
- Children's Hospital Los Angeles
- Other
- Eligibility
- 18 Years to 59 Years · Female only
- Enrollment
- 211 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Sarcoma, Sarcoma, Ewing, Desmoplastic Small Round Cell Tumor, Refractory Sarcoma, Osteosarcoma, Rhabdomyosarcoma
- Interventions
- PEEL-224, Temozolomide, Vincristine, Pegfilgrastim, Filgrastim
- Drug · Biological
- Lead sponsor
- David S Shulman, MD
- Other
- Eligibility
- 12 Years to 49 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Lymphoma, Lymphoma, B-Cell
- Interventions
- Rituximab, Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, CAPP-seq
- Drug · Device
- Lead sponsor
- Jennifer Amengual
- Other
- Eligibility
- 15 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Stanford, California • New York, New York
- Conditions
- AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
- Interventions
- Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (50 mg/kg D3, D4), PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Post-transplant Abatacept, Post-transplant Ruxolitinib, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Supportive Care: Prophylaxis against infections, Supportive Care: Lipid elevations, Study treatment compliance, Prohibited Concomitant Therapy, Permitted Concomitant Therapy
- Drug · Procedure · Other
- Lead sponsor
- Center for International Blood and Marrow Transplant Research
- Network
- Eligibility
- 18 Years to 66 Years
- Enrollment
- 358 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more
- Conditions
- Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
- Interventions
- Adagrasib, Anti-PD-L1 Monoclonal Antibody, Anti-PD1 Monoclonal Antibody, Bevacizumab, Biopsy Procedure, Biospecimen Collection, Chemotherapy, Computed Tomography, Durvalumab, Magnetic Resonance Imaging, Monitoring, Positron Emission Tomography, Surveillance, Tremelimumab
- Drug · Biological · Procedure + 2 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 535 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 13
- States / cities
- Goodyear, Arizona • Corona, California • Duarte, California + 10 more
- Conditions
- Alzheimer's Disease
- Interventions
- Sagramostim, Saline -- placebo comparator
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Teaching Behaviors, Sign Language Skills
- Interventions
- Strategic and Interactive Signing Instruction
- Behavioral
- Lead sponsor
- The University of Tennessee, Knoxville
- Other
- Eligibility
- 4 Years to 99 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Knoxville, Tennessee
- Conditions
- Infant Development
- Interventions
- Infant Formula
- Other
- Lead sponsor
- Aussie Bubs, Inc.
- Industry
- Eligibility
- 1 Day to 14 Days
- Enrollment
- 518 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 29
- States / cities
- Phoenix, Arizona • Centennial, Colorado • Jacksonville, Florida + 25 more